Liu B, Cao H M, Li G Y, Liu M, Feng J, Li J, Wang Q
Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
J Int Med Res. 2011;39(6):2314-22. doi: 10.1177/147323001103900630.
This randomized, double-blind, parallel-design study compared the short-term effects of rosuvastatin and atorvastatin on serum lipids and markers of inflammation and endothelial function in patients with stable atherosclerosis. Patients received either 10 mg/day rosuvastatin (n = 18) or 20 mg/day atorvastatin (n = 18), orally, for 4 weeks. Serum lipids, high-sensitivity Creactive protein (hsCRP), Rho-associated coiled-coil containing protein kinase (ROCK) activity and flow-mediated dilation (FMD) of the brachial artery were assessed before and after therapy. Both statins produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglyceride and hsCRP levels, and significant increases in FMD. Both statins significantly reduced ROCK activity and inhibition was significantly greater with rosuvastatin. There was no correlation between ROCK activity and LDL-C level in either group. There was a significant correlation between ROCK activity and FMD for both statins, but no correlations between FMD and LDL-C or hsCRP levels. Short-term treatment with either rosuvastatin or atorvastatin inhibits ROCK activity independent of cholesterol reduction, and improves endothelium dysfunction in patients with atherosclerosis.
这项随机、双盲、平行设计的研究比较了瑞舒伐他汀和阿托伐他汀对稳定型动脉粥样硬化患者血脂、炎症标志物和内皮功能的短期影响。患者口服10毫克/天瑞舒伐他汀（n = 18）或20毫克/天阿托伐他汀（n = 18），持续4周。在治疗前后评估血脂、高敏C反应蛋白（hsCRP）、含Rho相关卷曲螺旋的蛋白激酶（ROCK）活性和肱动脉血流介导的扩张（FMD）。两种他汀类药物均使总胆固醇、低密度脂蛋白胆固醇（LDL-C）、甘油三酯和hsCRP水平显著降低，FMD显著增加。两种他汀类药物均显著降低ROCK活性，瑞舒伐他汀的抑制作用显著更强。两组中ROCK活性与LDL-C水平均无相关性。两种他汀类药物的ROCK活性与FMD均显著相关，但FMD与LDL-C或hsCRP水平均无相关性。瑞舒伐他汀或阿托伐他汀短期治疗可独立于胆固醇降低抑制ROCK活性，并改善动脉粥样硬化患者的内皮功能障碍。
